Evidence map›Paper›PMID 39314946›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks.

Jakob German, Mattia Cordioli, Veronica Tozzo, Sarah Urbut, Kadri Arumäe, Roelof A J Smit, Jiwoo Lee, Josephine H Li, Adrian Janucik, Yi Ding and 23 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Jakob GermanInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID 0009-0002-1257-7782
Mattia CordioliInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4872-0520
Veronica TozzoDepartment of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000-0001-8538-9198
Sarah UrbutDivision of Cardiovascular Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-1135-9647
Kadri ArumäeInstitute of Psychology, Faculty of Social Sciences, University of Tartu, Tartu, Estonia.ORCID 0000-0001-9950-904X
Roelof A J SmitCharles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-9822-6726
Jiwoo LeeBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-0555-585X
Josephine H LiCenter for Genomic Medicine Massachusetts General Hospital, Boston, MA.ORCID 0000-0003-2314-0914
Adrian JanucikProgram in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Yi DingDepartment of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Akintunde AkinkuolieDepartment of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Henrike HeyneHasso Plattner Institut, Potsdam, Germany.
Andrea EoliDigital Engineering Faculty, University of Potsdam, Potsdam, Germany, Prof.-Dr.-Helmert-Str. 2-3, 14482.ORCID 0000-0002-6505-3117
Chadi SaadQatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar.
Yasser Al-SarrajQatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar.
Rania Abdel-LatifQatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar.
Shaban MohammedDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
Moza Al HailDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
Alexandra BarryCenter for Genomic Medicine Massachusetts General Hospital, Boston, MA.
Zhe WangCharles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8046-4969
Estonian Biobank research team
Tatiana CajusoInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Andrea CorbettaInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Pradeep NatarajanCenter for Genomic Medicine Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-8402-7435
Samuli RipattiInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Anthony PhilippakisEric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA, 02142.
Lukasz SzczerbinskiCenter for Genomic Medicine Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-6201-0605
Bogdan PasaniucDepartment of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Zoltan KutalikUniversity Center for Primary Care and Public Health, Lausanne, Switzerland.
Hamdi MbarekQatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha, Qatar.ORCID 0000-0002-1108-0371
Ruth J F LoosCharles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8532-5087
Uku VainikInstitute of Psychology, Faculty of Social Sciences, University of Tartu, Tartu, Estonia.ORCID 0000-0002-9375-9520
Andrea GannaInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Funding

UCLA Clinical and Translational Science InstituteUL1TR001881 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$9.9M
PRS Center for Admixed PopulationsU01HG011715 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$912k
Integrating case-control transcriptomic and genetic data in admixed individuals to identify disease genes for schizophrenia and bipolar disorderR01MH115676 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$430k
Elucidating the pharmacogenetics of the response to GLP-1 receptor agonists for type 2 diabetesK23DK131345 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$191k
NCATS NIH HHS UL1 TR001881NHGRI NIH HHS R01 HG009120NHGRI NIH HHS U01 HG011715NIDDK NIH HHS K23 DK131345NIMH NIH HHS R01 MH115676
6 · The paper itself

Abstract

Obesity is a significant public health concern. GLP-1 receptor agonists (GLP1-RA), predominantly in use as a type 2 diabetes treatment, are a promising pharmacological approach for weight loss, while bariatric surgery (BS) remains a durable, but invasive, intervention. Despite observed heterogeneity in weight loss effects, the genetic effects on weight loss from GLP1-RA and BS have not been extensively explored in large sample sizes, and most studies have focused on differences in race and ethnicity, rather than genetic ancestry. We studied whether genetic factors, previously shown to affect body weight, impact weight loss due to GLP1-RA therapy or BS in 10,960 individuals from 9 multi-ancestry biobank studies in 6 countries. The average weight change between 6 and 12 months from therapy initiation was -3.93% for GLP1-RA users, with marginal differences across genetic ancestries. For BS patients the weight change between 6 and 48 months from the operation was -21.17%. There were no significant associations between weight loss due to GLP1-RA and polygenic scores for BMI or type 2 diabetes or specific missense variants in the

Identifiers

PMID39314946
PMCPMC11419199

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.